Form D · Biotechnology
Myodenovo Inc.
Raleigh, NC · CIK 0001960653
Offering snapshot reported Feb 16, 2023 · SEC filing
- Reported sold
- $105K Offering amount: $2M
- Investors reported
- 2 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Dec 21, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Feb 16, 2023 | Initial | $105,000 | No comparison | 2 | SEC filing |
Offering details
- Securities
- Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-473621
No Sales Commissions or Finder's Fees have been or intended to be paid in connection with this offering.
Source: Form D, filed Feb 16, 2023. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| George Engelmayr | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
2735 Hidden Waters Cir.
Raleigh, NC, 27614
Raleigh, NC, 27614